|
GB8529014D0
(en)
|
1985-11-25 |
1986-01-02 |
Biogen Nv |
Enhanced secretion of heterologous proteins
|
|
AU597574B2
(en)
|
1986-03-07 |
1990-06-07 |
Massachusetts Institute Of Technology |
Method for enhancing glycoprotein stability
|
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5096815A
(en)
|
1989-01-06 |
1992-03-17 |
Protein Engineering Corporation |
Generation and selection of novel dna-binding proteins and polypeptides
|
|
US5198346A
(en)
|
1989-01-06 |
1993-03-30 |
Protein Engineering Corp. |
Generation and selection of novel DNA-binding proteins and polypeptides
|
|
US5350836A
(en)
|
1989-10-12 |
1994-09-27 |
Ohio University |
Growth hormone antagonists
|
|
US5959177A
(en)
*
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
|
EP1690934A3
(en)
*
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US6673986B1
(en)
*
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US6075181A
(en)
*
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6150584A
(en)
*
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
CA2104964A1
(en)
|
1991-02-28 |
1992-08-29 |
Ruth Sager |
Cancer diagnosis and therapy with tumor suppressor genes
|
|
FI941572L
(fi)
*
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
US5288931A
(en)
|
1991-12-06 |
1994-02-22 |
Genentech, Inc. |
Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
|
|
US5965132A
(en)
*
|
1992-03-05 |
1999-10-12 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
|
US5776427A
(en)
*
|
1992-03-05 |
1998-07-07 |
Board Of Regents, The University Of Texas System |
Methods for targeting the vasculature of solid tumors
|
|
AU5541094A
(en)
|
1992-10-30 |
1994-05-24 |
Consejo Superior De Investigaciones Cientificas |
Compositions and methods for modifying the regulatory activity of tgf-beta
|
|
US5830847A
(en)
*
|
1992-10-30 |
1998-11-03 |
Hsc Research & Development Limited Partnership |
Soluble TGF-β-binding endoglin polypeptides and homodimers
|
|
US7592428B1
(en)
|
1992-11-17 |
2009-09-22 |
Ludwig Institute For Cancer Research |
Antibodies which bind specifically to activin receptor like kinases
|
|
US6692925B1
(en)
*
|
1992-11-17 |
2004-02-17 |
Ludwig Institute For Cancer Research |
Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
|
|
KR950704485A
(ko)
*
|
1992-11-17 |
1995-11-20 |
로이드 제이. 오울드·에드워드 에이, 맥더모 2세 |
액티빈 리셉터-유사 키나제, 세린 트레오닌 키나제 도메인을 갖는 단백질 및 이들의 용도(activin receptor-like kinases, proteins having serine threonine kinase domains and their use)
|
|
JP3645258B2
(ja)
*
|
1993-01-12 |
2005-05-11 |
ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン |
増殖分化因子−５
|
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
US5541087A
(en)
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
|
US5925351A
(en)
|
1995-07-21 |
1999-07-20 |
Biogen, Inc. |
Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
|
|
EP0845006A2
(en)
|
1995-08-14 |
1998-06-03 |
Creative Biomolecules, Inc. |
Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof
|
|
ES2169864T3
(es)
*
|
1996-05-31 |
2002-07-16 |
Health Research Inc |
Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis.
|
|
US6190660B1
(en)
*
|
1996-05-31 |
2001-02-20 |
Health Research, Inc. |
Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
|
|
MX9701946A
(es)
|
1997-03-14 |
1998-04-30 |
Arturo Jimenez Bayardo |
Solucion oftalmica transportadora.
|
|
WO1998047531A2
(en)
|
1997-04-21 |
1998-10-29 |
Arch Development Corporation |
Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
|
|
EP0998561A4
(en)
|
1997-07-15 |
2004-08-18 |
Immunex Corp |
RECEPTOR DES TRAIL PROTEIN
|
|
EP1071765A4
(en)
|
1998-03-13 |
2003-01-15 |
Ludwig Inst Cancer Res |
Alk-1 responds to tgf-beta and signals through smad-1 and smad-5
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
ES2292236T3
(es)
|
1998-04-02 |
2008-03-01 |
Genentech, Inc. |
Variantes de anticuerpos y sus fragmentos.
|
|
US6413513B1
(en)
*
|
1998-05-22 |
2002-07-02 |
Entremed, Inc. |
Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
|
|
US20030012792A1
(en)
*
|
1998-05-22 |
2003-01-16 |
Holaday John W. |
Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
|
|
GB9912350D0
(en)
|
1999-05-26 |
1999-07-28 |
European Molecular Biology Lab Embl |
Modified cytokine
|
|
EP1187843A1
(en)
*
|
1999-06-03 |
2002-03-20 |
Human Genome Sciences, Inc. |
Angiogenic proteins and uses thereof
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
US7740841B1
(en)
|
2000-01-28 |
2010-06-22 |
Sunnybrook Health Science Center |
Therapeutic method for reducing angiogenesis
|
|
SI1255752T1
(sl)
|
2000-02-15 |
2007-12-31 |
Pharmacia & Upjohn Co Llc |
S pirolom substituirani zaviralci 2-indolinon protein kinaza
|
|
US7077836B2
(en)
*
|
2000-07-21 |
2006-07-18 |
Vein Rx, Inc. |
Methods and apparatus for sclerosing the wall of a varicose vein
|
|
AU2001283108A1
(en)
|
2000-08-03 |
2002-02-18 |
The University Of Utah Research Foundation |
Manipulation of arterial-venous identity
|
|
DE10043481A1
(de)
|
2000-09-04 |
2002-04-11 |
Vectron Therapeutics Ag Imt |
Humaner Antikörper gegen Endoglin (CD105) und seine Verwendung
|
|
EP1343782B1
(en)
|
2000-12-21 |
2009-05-06 |
SmithKline Beecham Corporation |
Pyrimidineamines as angiogenesis modulators
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
FI117667B
(fi)
|
2001-07-05 |
2007-01-15 |
Univ Zuerich |
Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
|
|
KR101072867B1
(ko)
|
2001-10-31 |
2011-10-17 |
유니버시티 오브 노스 텍사스 헬스 사이언스 센터 |
뼈 형태발생 단백질(ｂｍｐ), ｂｍｐ 수용체 및 ｂｍｐ 결합 단백질 및 녹내장 진단 및 치료에서 그의 용도
|
|
JP4547911B2
(ja)
|
2002-02-01 |
2010-09-22 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
リン含有化合物およびその用途
|
|
WO2003064628A2
(en)
|
2002-02-01 |
2003-08-07 |
Curagen Corporation |
Novel proteins and nucleic acids encoding same
|
|
US7045534B2
(en)
*
|
2002-02-12 |
2006-05-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of reducing angiogenesis
|
|
EP1534737A4
(en)
|
2002-04-29 |
2007-10-31 |
Univ Saint Louis |
PEPTIDANTAGONISTS OF MEMBERS OF THE TGF BETA FAMILY AND THEIR THERAPEUTIC APPLICATION
|
|
WO2004003163A2
(en)
|
2002-06-27 |
2004-01-08 |
University Of Utah Research Foundation |
Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
|
|
AU2003287444A1
(en)
|
2002-10-31 |
2004-05-25 |
The General Hospital Corporation |
Repairing or replacing tissues or organs
|
|
WO2005010049A2
(en)
|
2003-07-09 |
2005-02-03 |
Eli Lilly And Company |
Tgf-beta1 ligands
|
|
WO2005044849A2
(en)
|
2003-08-05 |
2005-05-19 |
Eli Lilly And Company |
Lp mammalian proteins; related reagents
|
|
US20050249723A1
(en)
*
|
2003-12-22 |
2005-11-10 |
Xencor, Inc. |
Fc polypeptides with novel Fc ligand binding sites
|
|
WO2005116850A2
(en)
|
2004-01-27 |
2005-12-08 |
Compugen Ltd. |
Differential expression of markers in ovarian cancer
|
|
WO2005116052A2
(en)
|
2004-04-27 |
2005-12-08 |
Research Development Foundation |
ANTAGONISM OF TGF-β SUPERFAMILY RECEPTOR SIGNALING
|
|
US7741284B2
(en)
*
|
2004-05-12 |
2010-06-22 |
Acceleron Pharma Inc. |
BMP10 propeptides and related methods
|
|
EP1771470B1
(en)
*
|
2004-07-23 |
2013-06-26 |
Acceleron Pharma Inc. |
Actrii receptor polypeptides, methods and compositions
|
|
US7897581B2
(en)
|
2005-02-24 |
2011-03-01 |
Massachusetts Eye & Ear Infirmary |
Methods and compounds for promoting vessel regression
|
|
CA2600505C
(en)
*
|
2005-03-10 |
2016-05-03 |
Morphotek, Inc. |
Anti-mesothelin antibodies
|
|
CA2621371C
(en)
|
2005-09-07 |
2018-05-15 |
Amgen Fremont Inc. |
Human monoclonal antibodies to activin receptor-like kinase-1
|
|
MX2008013394A
(es)
|
2006-04-21 |
2008-10-31 |
Wyeth Corp |
Metodos para tamizado de alta emision de lineas celulares.
|
|
WO2007143023A1
(en)
|
2006-05-31 |
2007-12-13 |
Beth Israel Deaconess Medical Center |
Soluble endoglin compounds and uses thereof for the treatment and prevention of cancer
|
|
KR20170012582A
(ko)
|
2006-11-02 |
2017-02-02 |
악셀레론 파마 인코포레이티드 |
Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도
|
|
US8642031B2
(en)
|
2006-11-02 |
2014-02-04 |
Acceleron Pharma, Inc. |
Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
|
|
US10059756B2
(en)
|
2006-11-02 |
2018-08-28 |
Acceleron Pharma Inc. |
Compositions comprising ALK1-ECD protein
|
|
KR20100090683A
(ko)
|
2007-11-09 |
2010-08-16 |
제넨테크, 인크. |
액티빈 수용체-유사 키나제-ｉ 길항제 조성물 및 사용 방법
|
|
TWI672151B
(zh)
|
2008-05-02 |
2019-09-21 |
艾西利羅製藥公司 |
調節血管新生與周圍細胞組成的方法與組合物
|
|
CA2724525A1
(en)
|
2008-05-15 |
2009-11-19 |
Acceleron Pharma, Inc. |
Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
|
|
EP2364371A4
(en)
|
2008-11-24 |
2012-05-02 |
Univ Loma Linda |
BIOMARKER FOR DETECTING HEADS AND HALSTUMORS
|
|
WO2010128158A1
(en)
|
2009-05-08 |
2010-11-11 |
Novartis Ag |
Diagnostic biomarkers for fibrotic disorders
|
|
EP2670847B1
(en)
|
2011-02-03 |
2016-10-05 |
XOMA Technology Ltd. |
Methods and materials for enhancing functional protein expression in bacteria
|
|
AU2013214779A1
(en)
|
2012-02-02 |
2014-09-04 |
Acceleron Pharma Inc. |
ALK1 antagonists and their uses in treating renal cell carcinoma
|
|
WO2014055869A1
(en)
|
2012-10-05 |
2014-04-10 |
Acceleron Pharma, Inc. |
Treatment of cancer with alk1 antagonists
|
|
AU2014388308A1
(en)
|
2014-03-28 |
2016-10-27 |
Acceleron Pharma, Inc. |
Use of activin receptor-like kinase 1 (ALK-1) antagonists in the treatment of cancer
|